Drug Trial Radar · NCT02260986
Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis
Last checked: Nov 19, 2026Latest source record: Oct 17, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
740
Actual
Start
Sep 2014
Primary completion
Aug 2015
Study completion Oct 2016
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- Collaborators
- Sanofi
- First posted
- Oct 9, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study was to demonstrate the efficacy of Dupilumab administered concomitantly with topical corticosteroid (TCS) through Week 16 in adult participants with moderate-to-severe atopic dermatitis (AD) compared to placebo administered concomitantly with TCS.
Conditions
- Atopic Dermatitis
Interventions
DupilumabDrug
Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
Placebo (for Dupilumab)Drug
Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
Topical Corticosteroid (TCS)Other
All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Investigator's Global Assessment (IGA) Score of "0" or "1" and Reduction From Baseline of ≥2 Points at Week 16Time frame: Baseline to Week 16
Locations
148 sites in 14 countries. Site status is shown where the registry gives one.
Site not named
Phoenix, Arizona
Site not named
Hot Springs, Arkansas
Site not named
Little Rock, Arkansas
Site not named
Encinitas, California
Site not named
Oceanside, California
Site not named
Palmdale, California
Site not named
San Diego, California
Site not named
New Haven, Connecticut
Site not named
Trumbull, Connecticut
Site not named
Edgewater, Florida
Site not named
Lake Worth, Florida
Site not named
Miami Lakes, Florida
Site not named
Orlando, Florida
Site not named
Tampa, Florida
Site not named
Alpharetta, Georgia
Site not named
Columbus, Georgia
Site not named
Savannah, Georgia
Site not named
West Dundee, Illinois
Site not named
Carmel, Indiana
Site not named
New Albany, Indiana
Site not named
Rockville, Maryland
Site not named
Ann Arbor, Michigan
Site not named
Bay City, Michigan
Site not named
Edina, Minnesota
Site not named
Fridley, Minnesota
Site not named
St Louis, Missouri
Site not named
Omaha, Nebraska
Site not named
Henderson, Nevada
Site not named
Verona, New Jersey
Site not named
Albuquerque, New Mexico
Site not named
Corning, New York
Site not named
New York, New York
Site not named
Smithtown, New York
Site not named
Stony Brook, New York
Site not named
Cincinnati, Ohio
Site not named
Norman, Oklahoma
Site not named
Oklahoma City, Oklahoma
Site not named
Lake Oswego, Oregon
Site not named
Portland, Oregon
Site not named
Exton, Pennsylvania
Showing 40 of 148 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.